Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/01.STR.0000240511.22775.a7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke.
Stroke
April 2008
Department of Neurology, University of Texas, Houston Medical School, Houston, Texas, USA.
Stroke: the dashed hopes of neuroprotection.
Lancet Neurol
January 2007
Hotchkins Brain Institute, University of Calgary, Foothills Hospital, Calgary, ABT2N 2T9, Canada.
NXY-059: a hopeful sign in the treatment of stroke.
Stroke
October 2006
Department of Neurology, Medical College of Georgia, Augusta, GA, USA.
Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.
Expert Opin Pharmacother
August 2006
National Stroke Research Institute, Level 1, Neurosciences Building, Austin Health, University of Melbourne, 300 Waterdale Road, Heidleberg Heights, Victoria 3081, Australia.
The administration of oral aspirin within 48 h and tissue plasminogen activator within 3 h of ischaemic stroke onset remain the only treatments that have been shown to have clinical benefit. There has been much excitement about neuroprotection over the last two decades, as it may minimise the harmful effects of ischaemic neuronal damage. Although each step along the ischaemic cascade offers a potential target for therapeutic intervention, and neuroprotection has shown benefit in animal studies, this has been difficult to translate to humans.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!